Welcome to ArkansasLifeScience.com
ArkansasLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About Arkansas's BioHistory
Why is there a biotechnology industry in Arkansas? Will the industry continue
to grow in Arkansas? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Arkansas BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Arkansas.
More AR BioHistory...
|
Local News...
Free News Release Posting & Archiving Service
- Nexavar significantly extends overall survival in liver cancer by 47 percent Bayer HealthCare and Onyx Pharmaceuticals announced that Nexavar(R) tablets significantly improved overall survival by 47.3 percent in patients in the Asia-Pacific region with advanced hepatocellular carcinoma, or primary liver cancer, versus those receiving placebo.
Bayer May 16, 2008
- Pharmacopeia's PS433540 achieves reductions in blood pressure in hypertensive patients Pharmacopeia announced that PS433540, its first-in-class Dual Acting Receptor Antagonist, showed statistically significant blood pressure reductions in a Phase 2a study in patients with mild to moderate hypertension.
Pharmacopeia May 16, 2008
- Respirators for general public use in public health medical emergencies now available Consumers concerned about an influenza outbreak can breathe a little easier: 3M has just released two new NIOSH N95 respirators for use by the general public in public health medical emergencies.
3M May 16, 2008
- Wyeth's major depressive disorder treatment Pristiq now available in U.S. pharmacies Wyeth Pharmaceuticals announced that PRISTIQ(TM), a new serotonin-norepinephrine reuptake inhibitor approved to treat adult patients with major depressive disorder, is now available in U.S. retail pharmacies nationwide. The recommended dose of PRISTIQ is 50 milligrams (mg) once daily.
Wyeth May 15, 2008
- ASCO study confirms importance of histology in treatment of non-small cell lung cancer Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer clinical trial.
Eli Lilly and Company May 15, 2008
More... | Submit News Release | National News
|